COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Learn more

Top stories

View all news

Geneva, 30 October 2020 – As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, the Vaccine Alliance, CEPI, and the…

Geneva, 28 October 2020 – Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility…

Around 450,000 girls aged 9-10 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia.

The COVID-19 vaccine race

Pre-clinical
154vaccines
are being explored in lab experiments and animals
PHASE 1
20 vaccines
are undergoing safety tests in healthy young individuals
Phase 2
12vaccines
are being tested in broader groups of people
Phase 3
10vaccines
are in large international trials to test their impact on COVID-19
APPROVED
0vaccines
are approved and licensed for general use

Learn more

#VaccinesWork

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Top VaccinesWork stories

View all stories

Geneva, 30 October 2020 – As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, the Vaccine Alliance, CEPI, and the…

It is clear that COVID-19 will persist much longer than anticipated. If countries do not take action soon to ensure the continuity of essential health services during the pandemic, the future death toll from communicable and noncommunicable…

Spending less time in the workplace usually results in lower rates of infectious disease, but workplace closures in Southeast Asia and the Western Pacific may be increasing exposure to the mosquitoes that transmit dengue virus.

Supported countries

Supported Countries

Our impact

Syringe >822 million children immunised
First aid locator >14 million future deaths prevented
Transitioned 16 countries transitioned from Gavi support
Billions >150 US$ billion in economic benefits for countries
Children 85% of the world's children reached by routine immunisation

Our mission: protect people's health

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Our partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Like. Follow. Share.

    Subscribe to our newsletter